HRP20130139T1 - Mipo inhibitori za lijeäśenje huntingtonove bolesti i multiple sistemske atrofije - Google Patents

Mipo inhibitori za lijeäśenje huntingtonove bolesti i multiple sistemske atrofije Download PDF

Info

Publication number
HRP20130139T1
HRP20130139T1 HRP20130139AT HRP20130139T HRP20130139T1 HR P20130139 T1 HRP20130139 T1 HR P20130139T1 HR P20130139A T HRP20130139A T HR P20130139AT HR P20130139 T HRP20130139 T HR P20130139T HR P20130139 T1 HRP20130139 T1 HR P20130139T1
Authority
HR
Croatia
Prior art keywords
treatment
huntington
disease
multiple system
mipo
Prior art date
Application number
HRP20130139AT
Other languages
English (en)
Croatian (hr)
Inventor
Hakan Eriksson
Werner Poewe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20130139T1 publication Critical patent/HRP20130139T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20130139AT 2007-08-23 2008-08-22 Mipo inhibitori za lijeäśenje huntingtonove bolesti i multiple sistemske atrofije HRP20130139T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95752307P 2007-08-23 2007-08-23
US95752507P 2007-08-23 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (1)

Publication Number Publication Date
HRP20130139T1 true HRP20130139T1 (hr) 2013-03-31

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130139AT HRP20130139T1 (hr) 2007-08-23 2008-08-22 Mipo inhibitori za lijeäśenje huntingtonove bolesti i multiple sistemske atrofije

Country Status (25)

Country Link
US (6) US20090054468A1 (esLanguage)
EP (1) EP2200616B1 (esLanguage)
JP (2) JP5247804B2 (esLanguage)
KR (1) KR101588464B1 (esLanguage)
CN (4) CN113633641A (esLanguage)
AU (1) AU2008289653B2 (esLanguage)
BR (1) BRPI0815681A2 (esLanguage)
CA (1) CA2698205C (esLanguage)
CY (1) CY1113714T1 (esLanguage)
DK (1) DK2200616T3 (esLanguage)
EA (1) EA017510B1 (esLanguage)
ES (1) ES2399846T3 (esLanguage)
HR (1) HRP20130139T1 (esLanguage)
IL (2) IL203738A (esLanguage)
ME (1) ME01510B (esLanguage)
MX (1) MX2010001983A (esLanguage)
MY (1) MY155633A (esLanguage)
NZ (1) NZ584135A (esLanguage)
PH (1) PH12014501180A1 (esLanguage)
PL (1) PL2200616T3 (esLanguage)
PT (1) PT2200616E (esLanguage)
RS (1) RS52665B (esLanguage)
SI (1) SI2200616T1 (esLanguage)
WO (1) WO2009025618A1 (esLanguage)
ZA (1) ZA201000848B (esLanguage)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
PE20161219A1 (es) 2011-11-11 2016-11-17 Pfizer 2-tiopirimidinonas
US9422280B2 (en) * 2012-03-29 2016-08-23 Basf Se N-substituted hetero-bicyclic compounds and derivatives for combating animal pests II
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
MX2019015578A (es) * 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
IL272043B (en) * 2017-07-17 2022-09-01 Astrazeneca Ab mpo inhibitors for use in medicine
US20240067651A1 (en) 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
CN115916164A (zh) * 2020-03-05 2023-04-04 拜奥海芬治疗学有限公司 用髓过氧化物酶抑制剂治疗肌萎缩侧索硬化症的方法
EP4146219A4 (en) * 2020-05-06 2024-05-22 Biohaven Therapeutics Ltd. PROCESS FOR PREPARING VERDIPERSTAT
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
UY40399A (es) 2022-08-18 2024-02-15 Astrazeneca Ab Inhibidores de mieloperoxidasa
US20240091231A1 (en) * 2022-08-31 2024-03-21 Astrazeneca Ab Pharmaceutical formulations
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012546A1 (en) * 1997-09-05 1999-03-18 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
SI2200616T1 (sl) 2013-03-29
MX2010001983A (es) 2010-03-10
IL240130A0 (en) 2015-09-24
CA2698205C (en) 2016-06-21
US20190099423A1 (en) 2019-04-04
CN105687199A (zh) 2016-06-22
US20110207755A1 (en) 2011-08-25
US20130059870A1 (en) 2013-03-07
CA2698205A1 (en) 2009-02-26
CN113633641A (zh) 2021-11-12
PT2200616E (pt) 2013-02-27
US20200405724A1 (en) 2020-12-31
NZ584135A (en) 2012-04-27
KR101588464B1 (ko) 2016-01-25
EP2200616B1 (en) 2012-12-26
EP2200616A4 (en) 2010-08-25
CN103638029A (zh) 2014-03-19
DK2200616T3 (da) 2013-03-04
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
ZA201000848B (en) 2012-07-25
MY155633A (en) 2015-11-13
PH12014501180A1 (en) 2015-08-24
RS52665B (sr) 2013-06-28
AU2008289653A1 (en) 2009-02-26
KR20100055434A (ko) 2010-05-26
CN101873857A (zh) 2010-10-27
EA017510B1 (ru) 2013-01-30
CY1113714T1 (el) 2016-06-22
EP2200616A1 (en) 2010-06-30
WO2009025618A1 (en) 2009-02-26
JP5247804B2 (ja) 2013-07-24
AU2008289653B2 (en) 2012-06-28
PL2200616T3 (pl) 2013-04-30
JP2013151547A (ja) 2013-08-08
BRPI0815681A2 (pt) 2015-02-18
HK1145141A1 (en) 2011-04-08
US10772890B2 (en) 2020-09-15
EA201000202A1 (ru) 2010-10-29
US20090054468A1 (en) 2009-02-26
ES2399846T3 (es) 2013-04-03
US20140221400A1 (en) 2014-08-07
ME01510B (me) 2014-04-20

Similar Documents

Publication Publication Date Title
HRP20130139T1 (hr) Mipo inhibitori za lijeäśenje huntingtonove bolesti i multiple sistemske atrofije
JP2010536849A5 (esLanguage)
IL324294A (en) Aryl-or heteroaryl-substituted benzene compounds
IL217044A (en) Derivatives of h5- [1,3] thiazolo [2,3- a] pyrimidine-5-oz or their salts acceptable in pharmacy, pharmaceuticals containing them, a method of pi3k kinase activity control and use thereof
PH12020500028A1 (en) Crystalline forms of a bruton`s tyrosine kinase inhibitor
BR112014015720A2 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
NL300929I2 (nl) Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl
ZA201005793B (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds,their use as mtor kinase and pi3 kinase inhibitors,and their synthesis
WO2008032072A8 (en) 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
HRP20170090T1 (hr) Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
IL192472A0 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2010056320A3 (en) Pi3k/mtor kinase inhibitors
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
ZA201100429B (en) Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors
NZ605469A (en) Nalbuphine-based formulations and uses thereof
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы